临床试验/NCT00325715

NCT00325715已完成1 期

AGN 201904 Versus Esomeprazole in the Prevention of Aspirin-induced Stomach or Upper Intestinal Damage in Healthy Volunteers

Allergan0 个研究点目标入组 150 人开始时间: 2006年4月最近更新: 2011年6月2日

适应症

干预措施

试验速览

阶段: 1 期
状态: 已完成
发起方: Allergan
入组人数: 150
主要终点: Stomach or upper intestinal erosions

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者记录与标识符相似试验

研究概览

简要总结

AGN 201904, a proton pump inhibitor, versus esomeprazole in the prevention of stomach or upper intestinal damage following administration of high-dose aspirin in healthy volunteers

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Prevention
盲法: Single

入排标准

年龄范围: 18 Years 至 65 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 是

入选标准

•Healthy Adult Volunteers who have provided written informed consent

排除标准

•Volunteers with a history of upper gastrointestinal disease or who have a current diagnosis of upper gastrointestinal disease.
•Female volunteers who pregnant, nursing, or planning a pregnancy
•Volunteers with a history of drug or alcohol abuse

研究组 & 干预措施

1

Experimental

干预措施: AGN 201904 (Drug)

2

Active Comparator

干预措施: esomeprazole (Drug)

结局指标

主要结局

Stomach or upper intestinal erosions

次要结局

未报告次要终点

研究者

发起方

Allergan

申办方类型

Industry

相似试验

撤回

2 期

Whether Proton Pump Inhibitors, Administered Prior to or After Surgery, Can Reduce the Incidence and/or Severity of Difficulty Swallowing Foods and/or Liquids,Following Anterior Cervical SurgeryDysphagiaGERDDegenerative Joint Disease

NCT03488147Icahn School of Medicine at Mount Sinai

招募中

不适用

COCA study

NL-OMON27946ErasmusMC Cancer Institute22

进行中（未招募）

1 期

The effects of the proton pump inhibitor esomeprazole alone or in combination with Coca-Cola on the absorption of Capecitabine in patients with cancer 'the COCA study'Colorectal carcinoma or other solid tumours

EUCTR2017-004465-27-NLErasmus MC Cancer Institute28

进行中（未招募）

1 期

The effects of the proton pump inhibitor esomeprazole on the bioavailability of afatinib (Giotrif®) in patients with lung cancer 'the BIO-GIO study'

EUCTR2017-001284-20-NLErasmus MC Cancer Institute

进行中（未招募）

1 期

The effects of the proton pump inhibitor esomeprazole on the bioavailability of regorafenib

EUCTR2015-005784-17-NLErasmus MC cancer institute14